Significance of native PLGA nanoparticles in the treatment of Alzheimer's disease pathology

Selkoe, 2016, The amyloid hypothesis of Alzheimer's disease at 25 years, EMBO Mol. Med., 8, 595, 10.15252/emmm.201606210 Lane, 2018, Alzheimer's disease, Eur. J. Neurol., 25, 59, 10.1111/ene.13439 Karch, 2015, Alzheimer's disease risk genes and mechanisms of disease pathogenesis, Biol. Psychiatr., 77, 43, 10.1016/j.biopsych.2014.05.006 Kim, 2018, Genetics of Alzheimer's disease, Dement Neurocogn Disord, 17, 131, 10.12779/dnd.2018.17.4.131 Perl, 2010, Neuropathology of Alzheimer's disease, Mt. Sinai J. Med., 77, 32, 10.1002/msj.20157 Straub, 2011, Toward a molecular theory of early and late events in monomer to amyloid fibril formation, Annu. Rev. Phys. Chem., 62, 437, 10.1146/annurev-physchem-032210-103526 Bisceglia, 2018, An integrated strategy to correlate aggregation state, structure and toxicity of Ass 1-42 oligomers, Talanta, 188, 17, 10.1016/j.talanta.2018.05.062 Revett, 2013, Glutamate system, amyloid ss peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology, J. Psychiatry Neurosci., 38, 6, 10.1503/jpn.110190 Chen, 2017, Amyloid beta: structure, biology and structure-based therapeutic development, Acta Pharmacol. Sin., 38, 1205, 10.1038/aps.2017.28 Lee, 2017, Towards an understanding of amyloid-beta oligomers: characterization, toxicity mechanisms, and inhibitors, Chem. Soc. Rev., 46, 310, 10.1039/C6CS00731G Re, 2012, Nanotechnology for neurodegenerative disorders, Nanomedicine, 8, S51, 10.1016/j.nano.2012.05.007 Saraf, 2019, Growing synergy of nanodiamonds in neurodegenerative interventions, Drug Discov. Today, 24, 584, 10.1016/j.drudis.2018.10.012 Tosi, 2019, Nanomedicine in Alzheimer's disease: amyloid beta targeting strategy, Prog. Brain Res., 245, 57, 10.1016/bs.pbr.2019.03.001 Danhier, 2012, PLGA-based nanoparticles: an overview of biomedical applications, J. Contr. Release, 161, 505, 10.1016/j.jconrel.2012.01.043 Wang, 2016, FDA's regulatory science program for generic PLA/PLGA-based drug program, Am. Pharmaceut. Rev., 20, 4 Ding, 2018, Recent advances of PLGA micro/nanoparticles for the delivery of biomacromolecular therapeutics, Mater. Sci. Eng. C Mater. Biol. Appl., 92, 1041, 10.1016/j.msec.2017.12.036 Baysal, 2017, Donepezil loaded PLGA-b-PEG nanoparticles: their ability to induce destabilization of amyloid fibrils and to cross blood brain barrier in vitro, J. Neural. Transm., 124, 33, 10.1007/s00702-016-1527-4 Fornaguera, 2015, Galantamine-loaded PLGA nanoparticles, from nano-emulsion templating, as novel advanced drug delivery systems to treat neurodegenerative diseases, Nanoscale, 7, 12076, 10.1039/C5NR03474D Sun, 2016, Design of PLGA-functionalized quercetin nanoparticles for potential use in Alzheimer's disease, Colloids Surf. B Biointerfaces, 148, 116, 10.1016/j.colsurfb.2016.08.052 Hajipour, 2017, Advances in Alzheimer's diagnosis and therapy: the implications of nanotechnology, Trends Biotechnol., 35, 937, 10.1016/j.tibtech.2017.06.002 Sanchez-Lopez, 2018, Memantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: in vitro and in vivo characterization, J. Nanobiotechnol., 16, 32, 10.1186/s12951-018-0356-z Jeon, 2019, Vitamin D-binding protein-loaded PLGA nanoparticles suppress Alzheimer's disease-related pathology in 5XFAD mice, Nanomedicine, 17, 297, 10.1016/j.nano.2019.02.004 Foroutanpay, 2018, The effects of N-terminal mutations on beta-amyloid peptide aggregation and toxicity, Neuroscience, 379, 177, 10.1016/j.neuroscience.2018.03.014 Wetzel, 2018, An aggregate weight-normalized Thioflavin-T measurement scale for characterizing polymorphic amyloids and assembly intermediates, Methods Mol. Biol., 1777, 121, 10.1007/978-1-4939-7811-3_6 Anand, 2019, Self-assembly of artificial sweetener Aspartame yields amyloid-like cytotoxic nanostructures, ACS Nano, 13, 6033, 10.1021/acsnano.9b02284 Anand, 2021, Mimosine functionalized gold nanoparticles (Mimo-AuNPs) suppress β-amyloid aggregation and neuronal toxicity, Bioact. Mater., 6, 4491, 10.1016/j.bioactmat.2021.04.029 Li, 2013, Mechanisms of transthyretin inhibition of beta-amyloid aggregation in vitro, J. Neurosci., 33, 19423, 10.1523/JNEUROSCI.2561-13.2013 Lakowicz, 1973, Quenching of fluorescence by oxygen. A probe for structural fluctuations in macromolecules, Biochemistry, 12, 4161, 10.1021/bi00745a020 Kim, 2019, PubChem 2019 update: improved access to chemical data, Nucleic Acids Res., 47, D1102, 10.1093/nar/gky1033 Gremer, 2017, Fibril structure of amyloid-beta(1-42) by cryo-electron microscopy, Science, 358, 116, 10.1126/science.aao2825 Sondergaard, 2011, Improved treatment of ligands and coupling effects in empirical calculation and rationalization of pKa values, J. Chem. Theor. Comput., 7, 2284, 10.1021/ct200133y Abraham, 2019 Pettersen, 2004, UCSF Chimera--a visualization system for exploratory research and analysis, J. Comput. Chem., 25, 1605, 10.1002/jcc.20084 Trott, 2010, Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J. Comput. Chem., 31, 455, 10.1002/jcc.21334 Wilkosz, 2018, Molecular insight into drug-loading capacity of PEG-PLGA nanoparticles for itraconazole, J. Phys. Chem. B, 122, 7080, 10.1021/acs.jpcb.8b03742 Jorgensen, 1996, Development and testing of the OPLS all-Atom force field on conformational energetics and properties of organic liquids, J. Am. Chem. Soc., 118, 11225, 10.1021/ja9621760 Berendsen, 1987, The missing term in effective pair potentials, J. Phys. Chem., 91, 6269, 10.1021/j100308a038 Dorosh, 2016, Probing oligomerization of amyloid beta peptide in silico, Mol. Biosyst., 13, 165, 10.1039/C6MB00441E Amritraj, 2013, Role of cathepsin D in U18666A-induced neuronal cell death: potential implication in Niemann-Pick type C disease pathogenesis, J. Biol. Chem., 288, 3136, 10.1074/jbc.M112.412460 Wang, 2020 Israel, 2012, Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells, Nature, 482, 216, 10.1038/nature10821 Yuan, 2011, Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells, PLoS One, 6, 10.1371/journal.pone.0017540 Wu, 2015, Stronger activation of SREBP-1a by nucleus-localized HBx, Biochem. Biophys. Res. Commun., 460, 561, 10.1016/j.bbrc.2015.03.069 Oakley, 2006, Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation, J. Neurosci., 26, 10129, 10.1523/JNEUROSCI.1202-06.2006 Di Pardo, 2012, Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice, Proc. Natl. Acad. Sci. U. S. A., 109, 3528, 10.1073/pnas.1114502109 Hawkes, 2006, Up-regulation of cation-independent mannose 6-phosphate receptor and endosomal-lysosomal markers in surviving neurons after 192-IgG-saporin administrations into the adult rat brain, Am. J. Pathol., 169, 1140, 10.2353/ajpath.2006.051208 Wu, 2017, The role of PTEN - HCV core interaction in hepatitis C virus replication, Sci. Rep., 7, 3695, 10.1038/s41598-017-03052-w Kodam, 2019, A role for astrocyte-derived amyloid beta peptides in the degeneration of neurons in an animal model of temporal lobe epilepsy, Brain Pathol., 29, 28, 10.1111/bpa.12617 Costa-Marques, 2019, Transplantation of bone marrow derived macrophages reduces markers of neuropathology in an APP/PS1 mouse model, Transl. Neurodegener., 8, 33, 10.1186/s40035-019-0173-9 Maulik, 2012, Mutant human APP exacerbates pathology in a mouse model of NPC and its reversal by a beta-cyclodextrin, Hum. Mol. Genet., 21, 4857, 10.1093/hmg/dds322 Galzitskaya, 2018, Studies of the process of amyloid formation by Abeta peptide, Biochemistry (Mosc.), 83, S62, 10.1134/S0006297918140079 Arosio, 2015, On the lag phase in amyloid fibril formation, Phys. Chem. Chem. Phys., 17, 7606, 10.1039/C4CP05563B Biancalana, 2010, Molecular mechanism of Thioflavin-T binding to amyloid fibrils, Biochim. Biophys. Acta, 1804, 1405, 10.1016/j.bbapap.2010.04.001 Van Nostrand, 2001, Pathogenic effects of D23N Iowa mutant amyloid beta -protein, J. Biol. Chem., 276, 32860, 10.1074/jbc.M104135200 Wei, 2008, Role of calpain and caspase in beta-amyloid-induced cell death in rat primary septal cultured neurons, Neuropharmacology, 54, 721, 10.1016/j.neuropharm.2007.12.006 Kayed, 2013, Molecular mechanisms of amyloid oligomers toxicity, J. Alzheimers Dis., 33, S67 Song, 2008, Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation, Eur. J. Neurosci., 28, 1989, 10.1111/j.1460-9568.2008.06498.x Huang, 2017, PLGA nanoparticles modified with a BBB-penetrating peptide co-delivering Abeta generation inhibitor and curcumin attenuate memory deficits and neuropathology in Alzheimer's disease mice, Oncotarget, 8, 81001, 10.18632/oncotarget.20944 Fan, 2018, Curcumin-loaded PLGA-PEG nanoparticles conjugated with B6 peptide for potential use in Alzheimer's disease, Drug Deliv., 25, 1091, 10.1080/10717544.2018.1461955 Kosel, 2019, Age-related changes in social behaviours in the 5xFAD mouse model of Alzheimer's disease, Behav. Brain Res., 362, 160, 10.1016/j.bbr.2019.01.029 Penney, 2020, Modeling Alzheimer's disease with iPSC-derived brain cells, Mol. Psychiatr., 25, 148, 10.1038/s41380-019-0468-3 Ochalek, 2017, Neurons derived from sporadic Alzheimer's disease iPSCs reveal elevated TAU hyperphosphorylation, increased amyloid levels, and GSK3B activation, Alzheimer's Res. Ther., 9, 90, 10.1186/s13195-017-0317-z Giacomelli, 2005, Conformational changes of the amyloid beta-peptide (1-40) adsorbed on solid surfaces, Macromol. Biosci., 5, 401, 10.1002/mabi.200400189 Ansari, 2017, Current opinion in Alzheimer's disease therapy by nanotechnology-based approaches, Curr. Opin. Psychiatr., 30, 128, 10.1097/YCO.0000000000000310 Silva-Abreu, 2018, PPARgamma agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer's disease: in vitro and in vivo studies, Int. J. Nanomed., 13, 5577, 10.2147/IJN.S171490 Serpell, 2000, Alzheimer's amyloid fibrils: structure and assembly, Biochim. Biophys. Acta, 1502, 16, 10.1016/S0925-4439(00)00029-6 Cabaleiro-Lago, 2008, Inhibition of amyloid beta protein fibrillation by polymeric nanoparticles, J. Am. Chem. Soc., 130, 15437, 10.1021/ja8041806 Liao, 2012, Negatively charged gold nanoparticles inhibit Alzheimer's amyloid-beta fibrillization, induce fibril dissociation, and mitigate neurotoxicity, Small, 8, 3631, 10.1002/smll.201201068 Lee, 2011, Amyloid-beta forms fibrils by nucleated conformational conversion of oligomers, Nat. Chem. Biol., 7, 602, 10.1038/nchembio.624 Hayden, 2017, Identification of key regions and residues controlling Abeta folding and assembly, Sci. Rep., 7, 10.1038/s41598-017-10845-6 Thapa, 2016, Curcumin attenuates amyloid-beta aggregate toxicity and modulates amyloid-beta aggregation pathway, ACS Chem. Neurosci., 7, 56, 10.1021/acschemneuro.5b00214 Andarzi Gargari, 2018, The role of phenolic OH groups of flavonoid compounds with H-bond formation ability to suppress amyloid mature fibrils by destabilizing beta-sheet conformation of monomeric Abeta17-42, PLoS One, 13, 10.1371/journal.pone.0199541 Andrade, 2019, Natural compounds for Alzheimer's disease therapy: a systematic review of preclinical and clinical studies, Int. J. Mol. Sci., 20, 2313, 10.3390/ijms20092313 Kanchi, 2019, Polyproline chains destabilize the Alzheimer's amyloid-beta protofibrils: a molecular dynamics simulation study, J. Mol. Graph. Model., 93, 10.1016/j.jmgm.2019.107456 Stefanescu, 2020, Secondary metabolites from plants possessing inhibitory properties against beta-amyloid aggregation as revealed by Thioflavin-T assay and correlations with investigations on transgenic mouse models of Alzheimer's disease, Biomolecules, 10, 870, 10.3390/biom10060870 Bernstein, 2009, Amyloid-beta protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease, Nat. Chem., 1, 326, 10.1038/nchem.247 Eimer, 2013, Neuron loss in the 5XFAD mouse model of Alzheimer's disease correlates with intraneuronal Abeta42 accumulation and Caspase-3 activation, Mol. Neurodegener., 8, 2, 10.1186/1750-1326-8-2 Herrmann, 2011, Current and emerging drug treatment options for Alzheimer's disease: a systematic review, Drugs, 71, 2031, 10.2165/11595870-000000000-00000 Anand, 2014, Therapeutics of Alzheimer's disease: past, present and future, Neuropharmacology, 76 Pt, 27, 10.1016/j.neuropharm.2013.07.004 Avgerinos, 2021, Effects of monoclonal antibodies against amyloid-beta on clinical and biomarker outcomes and adverse event risks: a systematic review and meta-analysis of phase III RCTs in Alzheimer's disease, Ageing Res. Rev., 68, 10.1016/j.arr.2021.101339 Mukhopadhyay, 2021, A primer on the evolution of Aducanumab: the first antibody approved for treatment of Alzheimer's disease, J. Alzheimers Dis., 10.3233/JAD-215065 Cao, 2018, Advances in developing novel therapeutic strategies for Alzheimer's disease, Mol. Neurodegener., 13, 64, 10.1186/s13024-018-0299-8 Calzoni, 2019, Biocompatible polymer nanoparticles for drug delivery applications in cancer and neurodegenerative disorder Therapies, J. Funct. Biomater., 10, 10.3390/jfb10010004